Capmatinib Rahika 200mg Tablets

Q1: What is Capmatinib (Rahika) used for?

Capmatinib is a targeted therapy for metastatic non-small cell lung cancer (NSCLC) specifically with MET exon 14 skipping mutations, identified through FDA-approved molecular testing.

Q2: How does Capmatinib work?

Capmatinib is a selective MET kinase inhibitor. It blocks the MET receptor tyrosine kinase signaling pathway, preventing MET-driven tumor cell proliferation, survival, and migration.

Q3: What test is needed before starting Capmatinib?

An FDA-approved test to confirm MET exon 14 skipping mutation in tumor tissue or blood (liquid biopsy) is required before starting Capmatinib. Without this mutation, the drug is not indicated.

Q4: How is Capmatinib administered?

Take 400mg (two 200mg tablets) orally twice daily, totaling 800mg/day, with or without food. Swallow tablets whole — do not crush or split.

Q5: How long is Capmatinib treatment continued?

Treatment continues until disease progression or unacceptable toxicity, as determined by your oncologist. Response is monitored by imaging and clinical assessment.

Q6: What are the most common side effects?

Common side effects include peripheral edema (hand/foot swelling), nausea, fatigue, vomiting, dyspnea, and decreased appetite. These are generally manageable.

Q7: What serious side effects require emergency care?

Seek immediate care for: new or worsening respiratory symptoms (possible interstitial lung disease/pneumonitis), signs of liver damage (jaundice, dark urine), or severe skin reactions to sunlight (photosensitivity).

Q8: Does Capmatinib interact with other drugs?

Capmatinib interacts with CYP1A2 substrates (certain antidepressants, theophylline) and P-gp substrates. Strong CYP3A4 inducers may reduce efficacy. Always disclose all medications to your oncologist.

Q9: Can Capmatinib be taken with food?

Yes, Capmatinib can be taken with or without food. Consistent timing twice daily is more important than meal timing.

Q10: Is Capmatinib safe during pregnancy?

No. Capmatinib can cause fetal harm. Women of reproductive potential must use effective contraception during treatment and for 1 week after the last dose. Male patients should use contraception for 1 week after treatment.

Q11: What monitoring is required during Capmatinib treatment?

Regular monitoring includes liver function tests (before starting, every 2 weeks for 3 months, then monthly), renal function, and imaging to assess tumor response. Report any new respiratory symptoms promptly.

Q12: Is Capmatinib available without a prescription?

No. Capmatinib is a prescription-only targeted oncology drug requiring oncologist supervision, molecular testing, and regular monitoring.